The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

The Impact of CTCs on Survival in Cervical Cancer

Krishnansu S. Tewari, MD, FACOG, FACS
Published Online: 5:48 PM, Tue March 31, 2015
Krishnansu S. Tewari, MD, FACOG, FACS, Professor and Director of Research, Principal Investigator, NRG Oncology and GOG Legacy, University of California Irvine, discusses a trial looking at the impact of circulating tumor cells (CTCs) on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer.

<<< View more from SGO 2015

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.